ERBB2 and neoplasm: Our data support that SKBR3-pool2- and BT474-HR20-derived tumor xenograft models serve as an excellent in vivo system to test the antitumor activity of other HER2-targeted therapies, including lapatinib against trastuzumab-resistant BC.